pharma · Severe, Refractory Systemic Lupus Erythematosus · Refractory Progressive Multiple Sclerosis · AUTL
Autolus
Autolus GmbH
Tubulis is a pharma organization headquartered in Munich, DE. It trades on NYSE under ticker AUTL. Primary therapeutic focus areas include Severe, Refractory Systemic Lupus Erythematosus, Refractory Progressive Multiple
Munich, Bayern 81377, DE HQ
117 Employees
Public company Type
AUTL · NYSE Ticker
Company details
- Status
- Public
- HQ
- Munich, Bayern 81377, DE
- Employees
- 117
- Programs
- 16
- Drugs
- 17
- Patents
- 49
AUTO3
Phase 2 · mab · Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
AUTO3 for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) is a Phase 2 program (mab) at Autolus GmbH with 1 ClinicalTrials.gov record(s).
Internal code AUTO3-DB1
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Autolus GmbH
- Phase
- Phase 2
- Modality
- mab
- Indication
- Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
- Status
- terminated
- Trials
- 1